Heterogeneous immune cell composition in patients with combined immunodeficiency

Introduction: Combined immunodeficiencies (CIDs) are a severe class of inborn errors of immunity characterized by defective T cell development and function, often accompanied by impaired humoral and natural killer (NK) cell responses. Despite their shared clinical classification, the immunological heterogeneity within CIDs remains incompletely understood. This study aims to characterize the immune cell landscape in CID patients caused by disease-causing mutations in different genes to identify immunophenotypic patterns. Methods: using mass cytometry. Unbiased computational approaches were used to profile major immune populations and their subsets, and results were compared with healthy control samples to identify differences in immune cell frequencies and phenotypes. Results: T cell frequencies, whereas the BCL10-deficient patient had a near absence of NK cells, highlighting mutation-specific immune distributions. Detailed T cell subset analyses revealed increased naïve and decreased memory T cells in patients with BCL10 and IRF4 deficiencies, indicative of impaired T cell activation and memory formation. In contrast, ARPC1B deficiency was associated with elevated memory T cells and reduced naïve cells, suggesting thymic output defects. The Ezrin-deficient patient maintained a naïve-to-memory T cell ratio similar to controls despite an overall reduction in T cells. B cell abnormalities were consistent across patients, characterized by increased naïve B cells, decreased memory B cells, and severely diminished plasmablast frequencies. Discussion: Our findings reveal pronounced immunological heterogeneity among CID patients caused by different genetic defects, challenging the notion that CIDs constitute a uniform entity. Disease-causing gene-specific alterations in immune cell composition and differentiation states underscore the complexity of CID pathophysiology. Comprehensive immunophenotypic profiling offers valuable insights into distinct mechanistic pathways and may guide the development of tailored therapeutic strategies to improve clinical outcomes for CID patients.